Key Insights

Highlights

Success Rate

98% trial completion (above average)

Published Results

82 trials with published results (17%)

Research Maturity

379 completed trials (78% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

1.9%

9 terminated out of 486 trials

Success Rate

97.7%

+11.1% vs benchmark

Late-Stage Pipeline

7%

33 trials in Phase 3/4

Results Transparency

22%

82 of 379 completed with results

Key Signals

82 with results98% success

Data Visualizations

Phase Distribution

434Total
Not Applicable (46)
Early P 1 (8)
P 1 (331)
P 2 (16)
P 3 (3)
P 4 (30)

Trial Status

Completed379
Unknown54
Recruiting19
Withdrawn11
Not Yet Recruiting9
Terminated9

Trial Success Rate

97.7%

Benchmark: 86.6%

Based on 379 completed trials

Clinical Trials (486)

Showing 20 of 20 trials
NCT06426836Not ApplicableRecruitingPrimary

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

NCT05328778Phase 4CompletedPrimary

Pharmacokinetics and Pharmacodynamics of Sugammadex Dosed by Corrected Body Weight for Reversal of Vecuronium in Obese Patients

NCT02456974RecruitingPrimary

Antibiotic Dosing in Pediatric Intensive Care

NCT07812571Not Yet Recruiting

Tenofovir Exposures in Advanced Kidney Disease Study

NCT07813468Phase 1Recruiting

A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects

NCT06859723Phase 1Recruiting

High Potency Cannabis: Acute and Protracted Effects

NCT07583407Not ApplicableActive Not Recruiting

Pharmacokinetics of Kava and Kratom Alone and in Combination

NCT06665555Phase 1CompletedPrimary

Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years)

NCT07771309Not ApplicableCompleted

Study of Metabolic Absorption Rates of DHA-Taurine as a Source of Omega-3 Fatty Acids

NCT07422285Phase 1Completed

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose

NCT05099510Phase 1CompletedPrimary

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

NCT06650930Early Phase 1Completed

Pharmacokinetics of Oral Calcium Carbonate in Parturients

NCT07285967Phase 1Not Yet Recruiting

A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet

NCT06921590Phase 1CompletedPrimary

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects

NCT07560150Phase 2CompletedPrimary

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin Aspart (I004) and NovoLog® After Single-Dose Subcutaneous Administration to Healthy Volunteers

NCT07703904Phase 1Not Yet RecruitingPrimary

To Evaluate the Safety, Tolerability, Pharmacokinetics and the Effect of Food on the Hemay5259 Sustained-release Tablets in Healthy Subjects.

NCT06733675Phase 1Recruiting

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT05142592Phase 1Completed

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

NCT03911050Not ApplicableCompleted

Scavenging of Reactive Carbonyl Species by Apple Polyphenols in Human

NCT07663838Phase 1Not Yet Recruiting

A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)

Scroll to load more

Research Network

Activity Timeline